Johnson & Johnson plans more price transparency; eyes U.S. tax, healthcare changes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Johnson & Johnson (JNJ) PT Lowered to $141 at UBS Following 4Q Report
January 25, 2017 8:12 AM ESTUBS lowered its price target on Johnson & Johnson (NYSE: JNJ) to $141.00 (from $142.00) while maintaining a Buy rating following the company's 4Q earnings report.
Analyst Matt Miksic commented, "After making appropriate adjustments for year-over-year shipping day differences, JNJ's Q4 sales were up... More
